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ABSTRACT 
Malaria kills at least one million people each year, mostly children ⎯ a death every 30 
seconds. Almost one half of the world population is at risk from malaria. Antimalarial drugs are 
the only means for the treatment of about 500 million annual global malaria cases. Because of 
prevalent drug-resistance it is extremely urgent to identify new drug targets. Many proteins 
involved in eukaryotic signal transduction and cell cycle progression undergo post-translational 
lipid modification by a prenyl group. Protein prenyltransferases, which catalyze the post-
translational prenyl modification, have been established as a target for anticancer therapy. 
Research done in our laboratory has demonstrated recently that prenyl modification of proteins 
could be a novel target for the development of antimalarial drugs. 
The goal of this study is to understand the molecular mechanism of protein prenylation in 
Plasmodium. The key to use of prenyltransferase inhibitors for the pharmacological intervention 
is a thorough understanding of the in vivo prenylation pathways in the malaria parasite. 
Knowledge of the physiological functions of the cellular protein substrates of malarial 
prenyltransferases is an important first step in the elucidation of the mechanism of antimalarial 
action of inhibitors of protein prenylation.  
The research described in this thesis revealed the evidence for the existence of 
farnesylated and geranylgeranylated malaria parasite proteins. The study shows that the 
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dynamics of protein prenylation changes with the intraerythrocytic development cycle of the 
parasite. We detected that prenylated proteins in the 50 kDa range were mostly farnesylated and 
that the proteins in the 22-25 kDa range were mostly geranylgeranylated.  The prenylation of P. 
falciparum proteins is inhibited by prenyltransferase inhibitors. We have also demonstrated 
unique features of protein prenylation in P. falciparum compared to the human host such as 
farnesylation of proteins are sensitive to inhibition by geranylgeranyltransferase inhibitors..   In-
silico search of the malarial genome sequence identified potential  protein prenyltransferase 
substrates.  One of these substrates is a SNARE protein Ykt6 homologue. The malarial Ykt6 was 
recombinantly expressed and subjected to an in-vitro prenylation assay.  We showed that the 
recombinant Ykt6 was indeed a substrate for the  malarial prenyltransferase 
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1. INTRODUCTION 
Malaria dates back to the dawn of mankind.  Scientists have shown, by studying the 
parasite's family tree that malaria evolved from a chimp parasite nearly 8 million years ago; 
about the same time that pre-humans branched off the primate lineage. Researchers have been 
able to trace the ancestry of plasmodium falciparum, the most effective parasite in causing 
malaria in humans, to a small population that began between 9,500 and 23,000 years ago.   
Interestingly, this date coincides with the dawn of agriculture, which probably fueled the spread 
of malaria due to increased population densities and the increased availability of stagnant water 
in which mosquitoes could breed.   
Hypocrites wrote of malaria, some 2,500 years ago, and divided the fever into different 
types: quotidian (daily), tertian (alternate days) and quartan (every fourth day).  Allusions to the 
role of the mosquito in the transmission of the disease are plentiful throughout history.  As far 
back as 500 BC when Susruta, a Brahmin priest, gave a description of malarial fever that he is 
said to have attributed to mosquitoes. However, until the late 19th century it was generally 
believed that malaria (from Italian: mal' aria or bad air) was caused by a poisonous vapor or 
miasma released from swamps.  In 1816 Giovanni Rasori of Parma, while suffering from 
malarial fever in prison, was the first to doubt the "bad air" theory and to designate that a 
microorganism is responsible for the disease. The major breakthrough to confirm Parma’s 
hypotheses occurred in 1880 when the French physician, Charles Louis Alphonse Laveran, 
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discovered the malaria parasite while observing freshly drawn blood from a malaria patient. He 
noticed that after 15 to 20 minutes in an in vitro fluid state, the protozoa would emit extremely 
motile flagella. These motile organisms (which now are referred to as gametocytes) were 
originally called Oscillaria malariae. In 1886 Marchiafava and Celli gave the name Plasmodium 
to the genus. In 1887 William Henry Welch named the parasite that Laveran had discovered 
Plasmodium falciparum.   
It was during the 1890's that William George MacCallum's research led him to believe 
that Laveran's flagellated bodies played an important role in the life cycle of the parasite, in 
particular its extra-human phase. Sir Patrick Manson gave evidence that the parasite was not 
dependent upon man for its survival. Thus, he paved the way for the theory that the disease was 
transmitted by a "suctorial insect."  In 1897, Ronald Ross, who had been encouraged by Patrick 
Manson to investigate his hypotheses, used microscopy to detect the parasite in the wall of the 
stomach as well as in the digestive tract of the mosquito Anopheles Stephensi. The Italian 
Giovanni Battista Grassi demonstrated, in 1898, (with the Plasmodium vivax) the capacity of the 
Anopheles to transmit Plasmodium to humans.   
Malaria was eliminated from the United States and from most of Europe during the first 
half of the twentieth century through a concerted effort involving changes in agricultural 
practices, home construction, land use and vector control. The discovery that DDT 
(dichlorodiphenyltrichloroethane) was an effective insecticide in 1939 led the way to an 
international eradication program in the 1950s.  Problems with DDT, such as cost of spraying, 
resistance of communities to the spraying, and a high toxicity toward fish led to the interruption 
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of the program and subsequent survival of malaria as a disease with epidemic proportions.   The 
private sector lost interest in the fight against malaria due to the loss of profit motive as countries 
affected by the disease are underdeveloped and its citizens cannot afford newly developed drugs.
Thus, for many years, there was little change in mortality and morbidity from malaria. 
Then in 1957 the first chloroquine-resistant malaria parasites were discovered in Thailand and in 
South America in 1959 (CDC, 1978). From Southeast Asia and South America, chloroquine 
resistant strains of malaria spread worldwide.  The emergence of DDT-resistant vectors only 
added to the rapid increase in morbidity.  Alternative insecticides such as malathion are not an 
economically feasible treatment for many malaria endemic countries and recent studies have 
shown that resistance to this pesticide has also emerged.   By 1976, 42 species of Anopheles were 
resistant to one or more insecticides (Shuler, 1985).    
As chloroquine-resistant parasites have spread throughout Africa, the antifolate 
combination of pyrimethamine and sulphadoxine has increasingly become the drug of choice for 
the treatment of uncomplicated falciparum malaria. Malawi was the first African country to 
make this shift, in 1993, and pyrimethamine-sulphadoxine was designated the first-line drug in 
Kenya in 1998. In both Southeast Asia and South America, the exceptional pace of selection for 
resistance to pyrimethamine-sulphadoxine limited its useful therapeutic life (UTL) to about 5 
years. In East Africa, pyrimethamine-sulphadoxine has been the first-line drug for less than 5 
years, but selection of parasites resistant to pyrimethamine-sulphadoxine is already evident, and 
the clinical effectiveness of this formulation is decreasing (Sibley, 2001).  Figure 1 illustrates a 
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current geographic distribution of strains resistant to chloroquine and sulphadoxine-
pyrimethamine. 
Although malaria is an important health problem in some parts of Asia and South 
America, its main impact is in sub-Saharan Africa where at least 90% of deaths from malaria 
occur. Recent attempts to tally the global burden of malaria indicate that at least one million 
deaths occur from malaria each year i.e., a death from malaria every 30 seconds (Snow, 1999). 
There are approximately 500 million people at risk from malaria in Africa. Beyond the appalling 
toll on human life, the economic cost of malaria is staggering because of the cost due to the 
management of the disease. Countries where malaria has reached endemic proportions are 
among the poorest in the world.  Thus, overall economic impact of malaria is likely to be much 
more substantial than suggested by estimates of direct costs alone since malaria contributes to 
loss in production output, lack of foreign investment and improper education due to frequent 
infection in children.  
1.1 The Organism 
 
The causative agent of malaria is a parasitic protozoan called Plasmodium.   Four species 
of Plasmodium are known to infect humans: falciparum, vivax, ovale, malarium.   The genome 
of Plasmodium falciparum is 22.8 megabases (Mb) long and contains 14 chromosomes ranging 
in size from 0.643 to 3.29 Mb.  To date, it is the most (A + T)-rich genome sequenced with 
80.6% A + T.  Approximately 5,300 protein-encoding genes were identified (Gardner, 2002).   
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Figure 1 Global status of resistance to chloroquine and sulphadoxine/ pyrimethamine, the two most widely used 
antimalarial drugs. Data are from the WHO. [originally from Ridley, 2002] 
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The mitochondrial genome of Plasmodium is small (about 6 kb) and encodes no tRNA’s, which 
must be imported (Vaidya, 1989).  Plasmodium contains single rRNA clusters distributed on 
different chromosomes instead of long tandemly repeated arrays of rRNA genes.   The sequence 
of rRNA gene units vary  between units of similar size and the expression of these units is 
developmentally regulated, resulting in differential expression of rRNA units through 
development (Li, 1994).  About sixty percent of the predicted proteins appear to be novel and 
have no significant similarity to proteins from other organisms that are in the database. (Gardner, 
2002).  The apicoplast, a residual plastid located at the apical end of the parasite shared by all 
organisms in the phylum apicomplexa, has a 35-kb genome (Wilson, 1996).  Because of its small 
size proper function of the apicoplast, as well as the mitochondria, requires enrichment of its 
proteome by the nucleus (Vaidya, 1989; Waller, 1998). 
1.2 Life Cycle 
 
The life cycle of Plasmodium falciparum is split between two hosts: the Anopheles 
mosquito and humans.   Only the female mosquito plays host to Plasmodium.  When the female 
mosquito feeds on an infected human, she may ingest sexual stages of the parasite and will 
become a breeding ground for the parasite.  Once ingested, gametocytes will go through 
gametogenesis and escape from the host erythrocyte. Several factors participate in the induction 
of gametogenesis, including a drop in temperature, an increase in carbon dioxide, and mosquito 
metabolites.  The sexual forms of the parasite are referred to as microgametes and 
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macrogametes, male and female respectively.  In the mid-gut microgametes become 
exflagellated and fertilize the macrogamete leading to a zygote.  The zygote develops into a 
motile ookinete, which subsequently becomes an oocyst. Once in the outer wall of the midgut, 
the oocyst undergoes sporogony: multiple rounds of asexual replication resulting in the 
production of sporozoites. Once the oocyst ruptures, it releases sporozoites into the hemocoel of 
the mosquito.  The sporozoites eventually invade the salivary gland of the mosquito where they 
will stay until the mosquito takes another blood meal and subsequently begins the asexual stage 
of life cycle (Harrison, 1978; Schmidt, 1989). 
In humans, infection is initiated when sporozoites are injected with the saliva of a feeding 
mosquito into the subcutaneous tissue, and less-frequently directly into the bloodstream; from 
there, sporozoites travel to the liver. Sporozoites pass through several hepatocytes before 
invasion is followed by parasite development (Mota, 2001). 
Inside the hepatocyte, the parasite undergoes an asexual replication known as 
exoerythrocytic schizogony. The sporozoites will develop into tens of thousands of merozoites, 
which can each invade an erythtrocyte (RBC) once released from the liver.  A small proportion 
of asexual parasites convert to gametocytes that are essential for transmitting the infection to 
others through female anopheline mosquitoes.  The disease in caused by asexual parasites 
multiplying in RBCs.  This process usually takes 48 hours, however some parasites from 
Plasmodium vivax and Plasmodium ovale go thorough a dormant period instead of readily 
entering exoerythrocytic schizogony.  These Hypnozoites will move out of dormancy after 
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several weeks to months (or years) have passed since the primary infection and are responsible 
for relapses (Krotoski, 1989). 
Once a merozoite is released into the bloodstream, it will flow until it binds an RBC.  At 
this point, the merozoite will undergo apical reorientation.  Receptors that mediate invasion of 
the RBC (and liver) are found in the rhoptries, micronemes and dense granueles which are 
contained within the apicoplast (Adams, 1990). These organelles will only release the receptors 
after contact with the RBC has been made, thus avoiding neutralization by antibodies.  The 
merozoite induces a small depression in the erythrocyte membrane. The area of the RBC to 
which the merozoite is attached thickens and forms a junction with the plasma membrane of the 
merozoite.  As the merozoite enters the invagination in the erythrocyte surface, the junction— in 
the form of a circumferential zone of attachment between the erythrocyte and merozoite—moves 
along the confronted membranes to maintain its position at the orifice of the invagination.  This 
process will continue until the entire merozoite is eveloped by the RBC membrane (Dvorak, 
1995). 
There are two known families of parasite receptors involved in invasion:  the duffy-
binding like proteins (DBL) and the reticulocyte-binding-like (RBL) proteins. These receptors 
determine the flexibility for invasion by the various Plasmodium species (Adams, 1992; Rayner, 
2001).  After entering the erythrocyte the parasite undergoes a growth period, followed by 
asexual replication. This stage of the lifecycle is marked by three microscopically distinct 
phases: ring, trophozoite and schizont.  In the ring stage, the parasite spreads itself into a thin 
biconcave disc, thicker around its perimeter where the elongated nucleus is present and thinner in 
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the middle, giving it the appearance of a ring in Giemsa-stained blood smears. The parasite is 
contained within membrane-lined cavity known as the parasitophorous vacuole (PV). From this 
vacuole, the parasite feeds on hemoglobin and takes up other nutrients from the plasma through 
its cytostome.  As the ring stage enlarges, the parasite begins to synthesize molecules specific to 
this stage.  Some of these molecules are exported to the RBC membrane, thus modifying its 
composition.  
The ring eventually grows into the more rounded trophozoite stage.  This is the most 
metabolically active stage of the parasites asexual life cycle. The parasite continues to modify 
the RBC membrane so that it can now adhere to endothelial tissues and increase its permeability 
to nutrients. The feeding on hemoglobin continues, and the heme products of hemoglobin 
digestion crystallize into particles of dark pigment, haemozoin, scattered within the food 
(pigment) vacuole 
The end of the trophozoite phase comes with the onset of nuclear division without 
cytokinesis.   The schizont stage consists of 3 to 5 rounds of nuclear replication followed by a 
budding process.  At the end of the schizont stage, the parasite bursts its host cell and releases 
merozoits, which are capable of re-entering the asexual stage of the life cycle.  The rupture of 
schizont induces the production of cytokines, particularly tumor necrosis factor (TNF) 
(Kwiatkowski, 1989).  Even though most gametocytes develop from liver schizonts, and 
prolonged asexual lifecycles decrease the chance of a parasite re-entering the sexual life cycle, 
changes in environment such as increased parasitemia can induce formation of gametocytes from 
the asexual erythrocytic stages.  Figure 2 illustrates both stages of the malarial life cycle. 
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Figure 2.  The malaria parasite life cycle involves two hosts.  During a blood meal, a malaria-infected female 
Anopheles mosquito inoculates sporozoites into the human host .  Sporozoites infect liver cells and mature into 
schizonts , which rupture and release merozoites .  (Of note, in P. vivax and P. ovale a dormant stage 
[hypnozoites] can persist in the liver and cause relapses by invading the bloodstream weeks, or even years later.)  
After this initial replication in the liver (exo-erythrocytic schizogony ), the parasites undergo asexual 
multiplication in the erythrocytes (erythrocytic schizogony ).  Merozoites infect red blood cells .  The ring 
stage trophozoites mature into schizonts, which rupture releasing merozoites .  Some parasites differentiate into 
sexual erythrocytic stages (gametocytes) .  Blood stage parasites are responsible for the clinical manifestations of 
the disease. The gametocytes, male (microgametocytes) and female (macrogametocytes), are ingested by an 
Anopheles mosquito during a blood meal .  The parasites’ multiplication in the mosquito is known as the 
sporogonic cycle .  While in the mosquito's stomach, the microgametes penetrate the macrogametes generating 
zygotes .  The zygotes in turn become motile and elongated (ookinetes) which invade the midgut wall of the 
mosquito where they develop into oocysts .  The oocysts grow, rupture, and release sporozoites , which make 
their way to the mosquito's salivary glands.  Inoculation of the sporozoites into a new human host perpetuates the 
malaria life cycle . [Originally from http://www.dpd.cdc.gov] 
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1.3 Attachment to Endothelium 
 
 Asexual parasites, in the trophozoite or schizont stage, and gametocytes can adhere to 
the endothelial tissues.  Thus, only the ring stage form of the parasite is found in the circulating 
blood (Newbold, 1999).  This adhesion process involves a mechanism where parasites first tether 
then roll before becoming firmly attached (Ho, 1999).   This process is mediated by an 
assortment of host proteins, however to this date, firm attachment under flow can be provided by 
two host receptors:CD36 and chondroitin sulphate A (CSA) (Cooke, 1994).  The parasite aids in 
this process by expressing and exporting a protein to the RBC membrane.    This protein  — P. 
falciparum erythrocyte membrane protein 1 (PfEMP1), is the only protein responsible for 
adherence on the infected RBC to a myriad of host receptors.  PfEMP1 is highly polymorphic, 
antigenically variant, and expressed on the erythrocyte surface at electron-dense protrusions 
termed knobs (Baruch, 1995).  PfEMP1 is encoded by the var gene.  There are 50-150 var genes 
on multiple parasite chromosomes, and some are in clustered arrangements (Su, 1995). 
1.4 Pathology and Clinical Features 
 
The parasite feeds on its host intracellular proteins, mainly hemoglobin. The changes in 
infected RBCs include spherical shape, membrane protuberances and appearance of parasite-
expressed protein in RBC membrane. These proteins lead to adhesion of host cell to other 
infected RBCs (clumping), to uninfected RBCs (resetting) and to endothelial tissue (Chu, 1997). 
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These malarial aggregates are central to the pathogenesis, resulting in blockage of veins and 
capillaries as well as inhibiting the clearing of the parasite by the spleen. 
Anemia in the first clinical manifestation of malaria and is an inevitable consequence of 
erythrocyte parasitization and involves the phagocytosis of parasitized and unparasitized cells, 
dyserythropoiesis ( abnormal RBC synthesis ) and decrease in erythropoiesis (RBC production) 
in bone marrow.  TNF, induced by schizont rupture, is considered an important aggravating 
factor in the pathogenesis of anemia (Clark, 1988). 
Another early sign of malaria infection is the enlargement and hardening of the spleen 
and Liver.  Blockage of splenic vessels may lead to hemorrhage and the liver assumes a brown, 
gray or even black color as a result of deposition of malaria pigment. Lactic acidosis  (as a result 
of glucose catabolism by RBC and loss of liver function) renal inflammation, lower blood 
pressure and tachycardia (lower heart rate) are also common.  Other organs affected by the 
parasite are the GI tract, lungs and placenta. 
Cerebral malaria is the most common complication and cause of death in severe P. 
falciparum infection.  Other complications include thrombocytopenia (a disorder in which the number of 
platelets is abnormally low), splenic rupture, dilated hepatic sinusoids containing Kupfer cells and 
parasitized RBCs, malarial hepatitis and renal failure. 
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 1.5 Antimalarials 
 
Jesuits in Peru discovered the first known natural antimalarial and analgesic, quinine, in 
the seventeenth Century. Quinine is an alkaloid derived from the bark of the Cinchona 
ledgeriana tree.  The use of quinine in the prevention of malaria was only surpassed by its 
synthetic derivatives quinacrine, primaquine and most notably chloroquine.    Quinine, and its 
synthetic analogs, remains the drug of choice for the treatment of malaria in most parts of the 
world (Riddley, 1998).  Side effects to quinine treatment are commonly referred to as 
cinchonism and may involve tinnitus (ringing in ear), hearing loss, dizziness, nausea, uneasiness, 
restlessness and blurring of vision.  Chloroquine is thought to exert its antimalarial effect by 
preventing the polymerization of toxic heme released during proteolysis of hemoglobin in the 
Plasmodium digestive vacuole (Sullivan, 1996).  
Another class of chemicals that have shown strong antimalarial activity are commonly 
referred to as antifolates.  Fully reduced folate cofactors are essential for the key one-carbon 
transfer reactions that are needed for nucleotide biosynthesis and amino-acid metabolism. At 
present, the most significant antifolate used to treat malaria is the combination of the 2,4-
diaminopyrimidine pyrimethamine, an inhibitor of dihydrofolate reductase (DHFR), and 
sulphadoxine, a sulphonamide that interferes with the action of dihydroopteroate synthase 
(DHPS), another enzyme in the folate pathway (Ridley, 2002; Takechi, 2001).    
Artemisinin (sweet wormwood or `qinghao') is an ancient Chinese herbal remedy used by 
Chinese herbal medicine practitioners for at least 2000 years. Its antimalarial activity was found 
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in1967 when Chinese scientists screened a series of traditional remedies for drug activities. 
(Meshnick et al., 1991). Incubation of infected RBC’s with artemisinin leads to parasite death 
through protein alkylation.  Artemisinin interacts with intraparasitic heme-iron (derived from the 
proteolysis of host cell hemoglobin), this interaction breaks the endoperoxide bridge found 
within artemisinin generating free radicals.  There are many theories as to how these free radicals 
induce parasite death.  The most accepted theory is that the artemisinin-derived free radicals 
appear to damage specific intracellular targets, possibly via alkylation. In the past decade, a 
general consensus has formed supporting the mechanism (Jefford, 1995; Hong 1994). 
A combination of atovaquone and proguanil has been found to be quite effective in 
treating malaria. It is believed that atovaquone inhibits electron transport and destabilizes the 
cytochrome bc1 complex, causing proton leakage to occur through this site, and that proguanil, 
through as yet unclear means, enhances this destabilization. This synergy results in a higher 
proton leakage at lower concentrations of atovaquone (srivastava, 1999) 
Resistance to treatment has emerged regardless of what regiment of drugs are used.   
Plasmodium falciparum drug-resistant malaria originates from chromosome mutations. Impaired 
chloroquine uptake by the parasite vacuole is a common characteristic of resistant strains, and 
this phenotype is correlated with mutations of the Pfmdr1, Pfcg2 and Pfcrt genes;   
Resistance to antifolates arises due to various point mutations of dihydrofolate reductase 
(DHFR) or DHPS. The S108N substitution in DHFR is the principal mutation associated with 
resistance to pyrimethamine or cycloguanil.  This mutation does not affect the enzyme’s 
operation on its natural substrate. Mutations in DHPS (A437G and K540E) account for 
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resistance to sulphadoxine.  Mutations in cytochrome bc1 gene (Y268N) yields atovaquone 
resistant parasites (Le Bras, 2003).   
There is currently no evidence for clinically relevant artemisinin resistance. However, 
since artemisinin derivatives are being widely used, artemisinin resistance is likely to develop 
eventually. Artemisinin-resistant strains of P. falciparum and P. yoelii have been obtained in the 
laboratory (Inselburg, 1985, Peters and Robinson, 1999).   
1.6 The future 
 
Malarial research is currently experiencing a renaissance period, which is fueled by the 
genome sequencing and an increase of funds for malaria research provided by established donors 
such as the National Institutes for Health, the Wellcome Trust and by new donors such as The 
Gates Foundation.  The Roll Back Malaria (RBM) initiative, a global partnership founded by the 
World Health Organization (WHO), the United Nations Development Program (UNDP), the 
United Nations Children's Fund (UNICEF) and the World Bank, has as its goal the reduction of 
malaria by 50% in the year 2010.  To reach this task, a great deal of attention has been aimed at 
understanding the sub cellular mechanism of the parasite.  A thorough understanding of the 
parasite’s molecular biology will be absolutely essential for the discovery of potential drug 
targets.   Protein prenyltransferases, enzymes required for the post-translational modification of 
proteins, have become a target for antimalarial development.  Furthermore, inhibitors of 
mammalian protein farnesyltransferase are being intensively developed by a large number of 
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major pharmaceutical companies because such compounds show profound ability to arrest the 
growth of transformed cells and cause shrinkage of tumor xenographs in experimental animals. 
Protein Prenylation is important for the malarial parasite’s growth and differentiation as 
prenyltransferase inhibitors have shown antimalarial activity  (Chakrabarti, 1998; Jomaa, 1999; 
Okhanda, 2001).  Thus, it is possible to target protein farnesyltransferase inhibitors (PFTIs) as 
anti-parasitic agents. PFTIs also have an advantage over new inhibitors since a wealth of 
information such as pharmacokinetic, toxicity, and bioavailability data is available from previous 
studies on mammalian systems. This "piggy back" approach allows rapid development of drugs 
and may result in inexpensive medicine. This is crucial because malaria is most prevalent in 
underdeveloped countries. 
1.7 Targeting Prenyltransferase 
 
Isoprenoids are compounds formed from isopentenyl pyrophosphate, which 
contains a five-carbon backbone also known as an isoprene unit.  P. falciparum has an 
unconventional method of synthesizing isoprenoids.  This method, also found in bacteria, algae 
and plants, is the DOXP pathway (Gardner, 2002; Jomaa, 1999).  The naming substance, 1-
deoxy-D-xylulose 5-phosphate, is the condensation product of glyceraldehyde 3-phosphate and 
pyruvate by DOXP-synthetase.  The pathway is shown in figure 3. 
The post translational modification process known as prenylation involves two types 
isoprenoids: the 15-carbon farnesyl pyrophosphate (FPP) and the 20-carbon  
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Figure 3.  The DOXP/MEP pathway of IPP biosynthesis in the plastids of plants.  The first five enzymes are known 
and have been numbered from 1–5. The second enzyme DXR can specifically be blocked by the herbicide 
fosmidomycin. This pathway also occurs in algae, the malaria parasite P. falciparum and in pathogenic bacteria. 
[Originally from Lichtenthaler, 2000; p.788] 
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geranygeranylpyrophosphate (GGPP).  Specifically, protein prenylation is the attachment of FPP 
and GGPP to conserved cysteine residues at or near the C-terminus of acceptor proteins.   
Prenylation reactions are catalyzed by three different enzymes: farnesyltransferase (Ftase), 
geranylgeranyltransferase (GGTase) type I, and GGTase type II. 
1.8 Prenyltransferases 
 
Protein farnesyltransferase (FTase) and protein geranylgeranyltransferase type-I 
(GGTase-I) catalyze the addition of farnesyl and geranylgeranyl groups to proteins that have a C-
terminal CAAX motif. In this motif, the ‘C’ is a cysteine to which the isoprenoid is covalently 
linked, the ‘A’ is an aliphatic amino acid, and the ‘X’ residue provides prenylation specificity.  
In mammalian systems, protein farnesyltransferase (PFT) farnesylates the cysteine residue in 
carboxyl-terminal containing an X conferring methionine, glutamine, serine, threonine, or 
cysteine and protein geranylgeranyl transferase-I (PGGT-I) shows specificity for X residues 
conferring leucine (Moores, 1991). FTase and GGTase I are metalloenzymes composed of an α 
and a β subunit.  Both enzymes require zinc to function whereas GGTase I also requires 
Magnesium (Reiss, 1992).  They share an identical, 48 kDa. α subunit. The  β subunit of Ftase 
and GGTase are 46kDa and 43kDa, respectively (Andres, 1993; Moomaw, 1992; Yokoyama, 
1991).  Binding of the prenyl group and acceptor protein is mediated by the β subunit whereas 
the catalytic activity is controlled by the α subunit (Park, 1997; Zhang, 1996).    
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The secondary structure of the α subunit of FTase is composed of series of helices, which 
form several helical hairpins.  These helical hairpins form a double-layered, right-handed 
superhelix resulting in a crescent shape that partly envelops the β subunit (Park, 1997).  The 
exact reaction path of PFTase has been elucidated (Long, 2002).  The first step in the process 
involves the binding of the prenyl group substrate to the enzyme.  The prenyl group binds to an 
enzymatic cleft in the β subunit.   This cleft has precise dimensions so that if the correct prenyl 
group becomes attached, its terminal carbon will interact with the bottom of the cleft and the 
diphosphate group will interact with the zinc ion located atop the cleft.  The acceptor protein 
binds next.  It is important to note that the prenyl substrate forms a substantial part of the binding 
domain for the acceptor protein.   During a transitional state the phosphodiester bond is rotated 
repositioning the α-phosphate and allowing interaction between the C1 atom of the isoprenoids 
and the cysteine thiolate of the acceptor protein.  The diphosphate group’s negative charges are 
mediated by tyrosine 300 on the β subunit, lysine 164 on the α subunit and magnesium (in 
GGTase I, magnesium is replaced by lysine 311 on the β subunit).  The zinc and the C – S bond 
of the cysteine thiolate mediate a nucleophilic attack on C1 of the isoprenoids.   This zinc-
catalyzed sulfur alkylation mechanism is likely to be the same mechanism used by all protein 
prenyltransferases.  The substrate, prenylated protein, is only released when fresh FPP substrate 
binds to Ftase (Long, 2002; Huang 2000).  This reaction is shown in figure 4.   
  Two additional modifications are required to obtain a finished product.  First, the 
three tailing amino acids of the prenylated protein are removed by an endopeptidase.   
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Figure 4.  Structures along the FTase reaction path. 0, Structure of unliganded FTase6 (PDB number 1FT1; red,a-
subunit; blue,b-subunit). 1–4, Observed ligand conformations in FTase crystal structures. 1, Farnesyl diphosphate 
substrate (FPP, blue) bound to FTase 
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The second and final additional step involves the addition of a methyl group to the prenylated 
cysteine’s carboxyl, group.   In this step, an S-adenosyl-L-methionone acts as a methyl donor and 
the reaction is mediated by a methyltransferase (Zhang, 1996). The entire protein prenylation 
mechanism is illustrated in figure 5. 
Geranylgeranyltransferase II, also known as Rab GGTase, modifies proteins that do not contain 
the CAAX sequence. Instead, GGtase modifies proteins with -CC, -CXC, -CCX or -CCXX (in 
single letter amino acid and where X is any amino acid) c-terminal motif (Farnsworth, 1994). 
Three polypeptides are required for prenylation.  Two of these peptides form an αβ heterodimer, 
similar other prenyltransferases, and a 95kDa protein known as Rab escort protein (Rep1).  The 
50 kDa α subunit and the 38 kDa β subunit compose GGTase II (Seabra, 1992).  The αβ 
heterodimer shares about 30% sequence similarity with their FTase and GGTase counterparts 
and is responsible for the enzymatic function of GGTase II.  True to its name, the role of Rep 1 is 
to binding the protein substrates in a way that enzymatic action by the αβ heterodimer is still 
permited (Andres, 1993). Thus, the amino acid sequence on the protein substrate that mediates 
binding to Rep1 plays a crucial role in prenylation.  This explains why GGTase II can neither 
farnesylate nor be inhibited by short peptides. The α subunit of GGTase II contains two unique 
domains, an IG-like domain and an LRR domain, not found in its analogs that are responsible for 
binding of the Rep 1/protein substrate complex to the αβ heterodimer (Zhang, 2000). Rep will 
remain bound to the substrate protein throughout the prenylation process.  After prenylation, Rep 
delivers the modified protein to its target membrane. Similar to FTase I, GGTase II requires zinc 
for proper activity (Zhang 200).  The mechanism of geranygeranylation is shown in figure 5. 
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Figure 5. Overview of protein prenylation. Modification of C-terminal Cys residues (designated "C") for both the 
CaaX motif and Rab proteins are depicted.   In the case of CaaX motif proteins, famesylation is the modification 
shown. The minus sign (-) on particular forms designates those containing a free carboxyl group on the Cys residue 
and "C-Me" indicates that the carboxyl group has been methylated. Text gives further details. [Originally from 
Casey, 1996; p. 243] 
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1.9 Inhibitors of Protein Prenylation  
 
As previously mentioned, inhibitors of mammalian protein farnesyltransferase have been 
developed due to their ability to arrest the growth of transformed cells and cause shrinkage of 
tumor in experimental animals. The design of PFT inhibitors has followed three main 
approaches: (i) pseudopeptide or peptidomimetic inhibitors which act competitively with the 
protein to be prenylated and noncompetitively with the isoprenoid FPP, (ii) FPP analogue 
inhibitors which, conversely, act competitively with the isoprenoid FPP and noncompetitively 
with the substrate protein and (iii) bisubstrate inhibitors which mimic the transition state of the 
two substrate complex.  Pseudopeptide inhibitors are molecules that closely resemble the CAAX 
motif.  In these molecules, some the peptide bonds have been reduced to their methylamino 
forms as a means to improve membrane permeability.  Complications with such inhibitors 
include the relative abundance of hydrolizable bonds, low absorption, rapid metabolism and low 
oral bioavailability.  Peptidomimetic inhibitors take this approach further by replacing the 
peptidic features of the tetrapeptide structure with simple, stable hydrophobic subunits such as a 
4-aminobenzoic acid ring and benzodiazepine (Qian, 1997).  The development of FPP analogue 
inhibitors encountered stifling problems such as the critical role FPP plays in cholesterol 
synthesis.  Thus, nonspecific binding of FPP analogues causes several side effects. Bisubstrate 
analogues contain the hydrophobic part of the farnesyl group and a mimic of the protein 
recognition site.  The potency and specificity reported for these initial compounds, against 
mammalian FTase, is very similar to that observed with the smaller CAAX mimetics (Graham, 
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1995; Gibbs, 1994). Although further modifications of bisubstrate analogs may improve potency       
beyond that achievable with FPP or CAAX mimetics alone, this gain in potency may be offset by 
the larger size of these molecules, which may compromise their pharmacological properties in 
vivo.  Figure 6 shows the structures of various inhibitors.  
This vast knowledge and abundance of farnesyltransferase inhibitors has stimulated 
researchers to determine the effect of these compounds on various organisms. It has been 
previously shown that inhibition of plasmodial farnesyltransferase can be achieved in vitro 
(Chakrabarti, 1998). Furthermore, the growth of P.falciparum in erythrocytic culture system is 
arrested efficiently                                                                                                                                                      
by peptidomimetics. Inhibition of farnesyltransferase activity as well as growth arrest by FTase 
inhibitors has been shown, in lower eukaryotes such as S. cervisiaecerae and trypanosomes.  
1.10 Prenylated Proteins 
 
It has been estimated that about 0.5% of all mammalian proteins are prenylated (Epstein, 
1991). Protein prenylation is essential for the proper localization and function of proteins central 
to signaling, nuclear architecture, and cell proliferation, such as small G proteins (Takai, 1992), 
heterotrimeric G protein γ-subunits (Yamane, 1990), nuclear lamins (Farnesworth, 1989), protein 
kinases (Inglese, 1992) and members of the Ras G protein superfamily, including Rab, Rho and 
Rac, that play crucial roles in protein trafficking and cytoskeletal organization (Desnoyers, 1996; 
Takai, 1993). Other proteins such as lamins, DNAJ, Ykt6 SNARE, PRL class of tyrosine  
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phosphatases, CENP-E and CENP-F have been found to be prenylated in mammalian systems.  
Scientist have yet to indentify the entire percentage of prenylated proteins in mammals, which 
would tally to some 150 to 200 proteins.  Protein prenylation also plays a critical role in diverse 
cellular processes in many organisms other than mammalian cells including yeasts and plants 
(Zhang, 1996; Yang, 2000; Pei, 1998).  
The goal of the proposed research is to characterize and understand protein prenylation in 
P. falciparum.  This will enable us to establish inhibitors of protein preylation as potential 
antimalarials. Specifically, following aims will be pursued: 
 
1. Analyze protein prenylation in P. falciparum 
 
2. Test the effect of FTase inhibitors  
 
3. Characterize prenylated proteins in Plasmodium. 
 
We will attempt to elucidate the types of proteins prenylated, the temporal localization of protein 
prenylation, and the effects of FTase inhibitors on protein prenylation, cell cycle and subcellular 
localization of prenylated proteins.  
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2. MATERIALS AND METHODS 
2.1 Culture 
 
P. falciparum strain 3D7, was maintained in a water-jacketed incubator at 37°C with an 
atmosphere of 5% C02 and 95% air. Parasite culture is stored in 10mm petri dishes, containing 
10mL culture per dish. The parasites' development and proliferation was monitored daily by light 
microscopy of Leukostat (Fisher) stained thin smears. The nutrient media of infected RBC 
culture plates was exchanged daily with fresh RP10S media: RPMI 1640 enriched with 11 mM 
glucose, 100 uM hypoxanthine, 0.2% (w/v) sodium bicarbonate, 25 mM HEPES pH 7.2, and 
10% human A (Rh+) blood serum. Culture plates were split according to estimated parasitemia 
within the next 24 hours. RBC from type A (Rh+) blood was acquired from the Central Florida 
Blood Bank.  The blood is washed, and diluted to a hematocrit of 5%, in a serum-free medium 
(Trager, 1976). 
2.2 Synchronization 
 
Synchronization was achieved through sorbitol treatment. Sorbitol lyses parasites in 
trophozoite and schizont stages by osmotic pressure; leaving the ring infected RBC’s intact. 
Culture plates were pooled in a 50 mL sterile conical centrifuge tube and spun at 200 ×  g for 5 
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minutes. The pellet was resuspended, in a volume five-fold greater than its own, in pre-warmed 
5% sorbitol solution and incubated in a 37°C water bath for 15 minutes. After incubation, the 
solution was centrifuged at 200 ×  g for 7 minutes. The pellet was washed twice with RPMI 
1640. Original media volume was added to resuspend the RBC pellet and solution was returned 
to petri dishes. 
2.3 Collection of Parasites 
 
Culture plates were allowed to grow to a parasitemia of 10-20% for harvesting. 
Pooled parasites in a 50 mL conical centrifuge tube were treated with 0.1% (w/v) saponin and 
incubated for 5 minutes at room temperature. After incubation the solution was centrifuged at 
4°C with a speed of 1800 ×  g for 7 minutes.  The pellet was washed twice in PBS, pH 7.2. The 
yield was approximately 4-5 × 107 parasites mL-1 of culture. All pellets were stored at -80°C 
until further use. 
2.4 Hypoxanthine Incorporation Assay 
 
Freshly synchronized parasitic culture was pooled in a 50 mL conical centrifuge tube and 
spun at 2000 µg for five minutes at 4°C.  The pellet is washed twice with five volumes and re-
suspended with hypoxanthine free medium.   If necessary, culture was split to a 3% - 5% 
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parasitemia.  [3H] Labeled hypoxanthine was added to a concentration of 1 mCi per ml.  
Inhibitors were dissolved in DMSO to a concentration of 25mM.  This stock solution was 
subsequently diluted immediately prior to assay.  Costar's Cell Culture Cluster 96 well plates 
were used.  In each well, 200µL of radiolabeled culture and 1µL of diluted drug or DMSO (as 
control) was added. Culture was returned to incubator for 24 hours, allowing hypoxanthine 
incorporation. A Tomtec's Mach II M Harvester 96 was used to transfer samples form 96 well 
plate to glass fiber membranes.  Corresponding sections of the membrane were cut, placed in 
five ml scintillation vials and immersed in three ml, Fisher Scintiverse, Scintillation Fluid. The 
radioactive count of each vial was detected by a Beckman LS500TD. The entire assay was 
performed in triplicate and the average of the results was plotted using Prism 2.0 software.  The 
effectiveness of each inhibitor is reported as an IC50 value, the concentration of inhibitor that 
reduces the count (i.e. the incorporation of hypoxanthine into nucleic acids) by 50%. 
2.5 Radiolabeling of P.falciparum Prenylated Proteins 
 
Synchronized parasite cultures were labeled with [3H]farnesol or [3H]geranylgeraniol, 
(American Radiolabeled Chemicals) at 6, 20, 32 hr. post synchronization.  These time points 
reflect ring, trophozoite and schizont stages, respectively.  Time points were incubated with 
radiolabeled prenyl group for 12 hours. Radiolabeled parasite proteins were isolated, resolved by 
SDS-PAGE, and detected by fluorography (details in section) 
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2.6 Inhibition of in vivo Radiolabeling of P. Falciparum Prenylated Proteins with 
Peptidomimetics 
 
Costar's Cell Culture Cluster 24 well plates were used.  Inhibitors FTI-277 and GGTI-298 
were purchased from Calbiochem. To each well, 1 mL of asynchronous P. falciparum culture 
and either 10 µCi of [3H]farnesol or [3H]geranylgeraniol was added.  For inhibition studies, 5µL 
of inhibitor (dissolved in DMSO) were added.  Samples were returned to the incubator for 24 
hours, allowing the prenyl groups to enter the cell and become attached to proteins.  The contents 
of each well were transferred to a 1.5mL minicentrifuge tube and spun at 1800 × g for 7 minutes.  
The pellet was washed twice with PBS.  The labeled parasites were released from RBC by 
treatment with 0.1% (w/v) saponin for 5 min followed by two washes with phosphate-buffered 
saline, pH 7.2 (Gibco) and centrifugation at 1800 × g for 7 min.  The parasite pellet was washed 
twice with PBS and lysed by addition of 24 µl of M-Per lysis reagent (Pierce). The lysed parasite 
extracts were mixed with 12µl 4X loading buffer and run on a 12% SDS-PAGE gel. The gel will 
ultimately be subjected to fluorography (as described below).  
 
2.7 Effect of Farnesyltransferase Inhibitors on P. falciparum Protein synthesis 
 
Synchronous culture with a parasitemia around 6% was pooled in a 50 mL conical 
centrifuge tube and spun at 2000 × g for five minutes at 4°C.  The RBC pellet was washed twice 
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with RPMI deficient in methionine and cysteine.  Washed RBC pellet was resuspended in 
methinonie and cysteine-deficient RP10S media enriched with Pro-mix L-[35S] in vitro cell 
labelling mix (Amersham Biosciences).  Radiolabeled malarial culture was transferred, in 1 ml 
aliquots, to a 24 well plate (costar).  Each well received either 5µl DMSO (control) or inhibitor.  
Samples were returned to the incubator for 24 hours to allow labeled amino acids to be used in 
protein synthesis. Cell extracts were prepared (as described in previous paragraph), resolved on 
SDS-PAGE, and subjected to autoradiography (as described below)  
2.8 Effect of FTI-277 on P. falciparum Maturation 
 
Freshly synchronized (6 h post-synchronization) parasitic culture, with approximately 6% 
parasitemia was transferred, in 1ml aliquots, into 24 well plates (costar).  Wells were treated 
with: 5l of DMSO (control), 5µM FTI-277 or 10µM FTI-277. Samples were returned to 
incubator and timepoints at 12, 24 and 36 hours past inhibitor treatment were collected and used 
to produce stained thin smears.  Images of stained thin smears were captured with a Zeiss 
Axioplan2 microscope equipped with a Hamamatsu color chilled 3CCD camera.  
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2.9 Indirect immunofluorescence microscopy 
 
Freshly synchronized (6 h post-synchronization ) parasitic culture, with approximately 
6% parasitemia was transferred, in 1ml aliquots, into 24 well plates (costar).  Wells were treated 
with: 5l of DMSO (control), 5µM or 10µM of FTI-277 and GGTI-298. Samples were returned 
to incubator and timepoints at 12, 24 and 36 hours past inhibitor treatment were allowed to 
adhere to poly-L-lysine-coated coverslips at 37 °C for 30 min. The slides were washed four times 
with phosphate-buffered saline, fixed in 4% paraformaldehyde (10 min at room temperature) and 
once again washed four times with phosphate-buffered saline. The cells were permeabilized and 
blocked by incubating slides in blocking solution (phosphate-buffered saline, 0.05% saponin, 5% 
bovine serum albumin) for 20 min at room temperature. The primary antibody, an affinity 
purified rabbit anti-farnesyl polyclonal antibody (Calbiochem), was diluted into a ration of 1:50 
in blocking solution.  The secondary antibody, an affinity purified Cy2-labeled goat anti-rabbit 
IgG (Jackson Immunoresearch Laboratories), was diluted into a ration of 1:200 in blocking 
solution. Samples were incubated for 90 minutes in with each antibody solution followed by 
three washes with phosphate-buffered saline. Nuclear staining was done with 1 µM 4',6-
diamidino-2-phenylindole (DAPI) for 5 min. The coverslips were mounted with gel/mount 
(Biomeda) on slides. The slides were viewed on a DeltaVision restoration microscope system 
(Applied Precision) equipped with a Nikon TE200 microscope and a Photometrix cooled CCD 
camera. DeltaVision software (SoftWoRx) was used for image deconvolusion 
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2.10 Preparation of ammonium sulfate fraction 
 
All steps were performed at or under 4°C. Parasite pellet from 2 liters of culture (200 
asynchronous plates at 10-20 % parasitemia) was resuspended in 20 mL of buffer A [50 mM Tris 
HC1, pH 7.5, containing one tablet of EDTA free protease inhibitor (Roche) 10mL-1]. The cell 
suspension was then sonicated with a microtip, using six 15-second cycles, and the resulting 
lysate was centrifuged at 100,000 × g with a 50.1 Ti rotor for 2 h (Beckman). The cleared lysate 
(S-100) was subjected to 0-50% ammonium sulfate [(NH4)2SO4] precipitation. It is important to 
grind the ammonium sulfate with a mortar and pestle and add it slowly to the cleared lysate I 
order to ensure complete dissolution and avoid temporary pH spikes. Once all the ammonium 
sulfate has been completely added, the solution is left on ice for 15 minutes. The solution was 
then centrifuged at 12,000 × g for 20 minutes.  The pellet was resuspended in 2 mL of buffer B 
(50 mM Tris-HCL, pH 7.5, 1mM DTT, 20 µM ZnCl2, 20 mM NaCl), injected into a Slide-A-
Lyzer 10,000 MWCO (Pierce) cassette and dialyzed against the same buffer for 4 hr. The 
dialysis buffer is exchanged at least once during this process.  The dialysed sample was then 
transferred into 1.5 mL cryogenic vials and stored at -80°C until further use. 
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2.11 Determination of Protein Concentration 
 
All protein concentrations were determined using the Bradford Assay (Bradford, 1976; 
Sambrook, 1989).  A mixture of 200 µ1 of Coomassie blue (Bio-rad protein 
assay concentrated dye reagents), 1,2,4,6, or 8 µg of a 1 µg/ul bovine serum albumin 
(Sigma) stock solution and ddH2O to bring the volume up to 1 mL was used to make a standard 
curve. Protein absorbance was read by UV spectroscopy (Beckman DU 640B 
Spectrophotometer) at 595 nm. Mixture of unknown samples was made in the same fashion as 
the standards with the exception that 2µL of Unknown sample was used instead of BSA 
standard. The concentrations of protein samples were determined by interpolation. 
2.12 Mono-Q Chromatography of P. falciparum protein farnesyltransferase activity 
 
Mono-Q chromatography was performed by modification of previously described 
methods (Vogt, 1995).  After dialysis of the reconstituted proteins form ammonium sulfate 
precipitation and determination concentration, 10ug of sample were loaded onto a Mono-Q 
(anion exchange) HR 5/5 column (Pharmacia Biotech) that had been equilibrated with buffer B 
(i.e. dialysis buffer). The column was then washed with 10 mL of Buffer B and the elution 
method consisted of a 15 mL linear gradient from 0.02 to 0.27 M NaCl, a 10mL step maintaining 
NaCl at 0.27 M and a 10 mL linear gradient from .27 to 1M NaCl.  The FTase was expected to 
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elute at a salt concentration of 270mM (Vogt, 1995). The buffer flow was maintained constant at 
the rate of 1 mL/min and 1 mL fractions were collected. An aliquot of 20 l from every other 
fraction was used to determine FTase activity (described next). Fractions with FTase activity 
were pooled and concentrated using a Centricon filter with a 10kDa cut-off.  Samples were spun 
at 3000  g until a minimal volume was reached.  The concentration and activity of the partially 
purified FTase were determined.  Samples were transferred, in 250L aliquots, into 1.5 mL 
cryogenic vials and stored at -80°C until further use. 
2.13 Assay for Farnesyltransferase Activity 
 
The scintillation proximity assay (SPA) was performed as directed by 
manufacturer’s recommendations (Amersham Biosciences). Protein samples incubated in assay 
buffer pH7.5 (50mM HEPES, 30mM MgCl2, 20mM KCl, 5mM DTT, 0.01% Triton X-100) with 
the laminin-B peptide and [3H] farnesylpyrophosphate for 1 hr at 37°C.  The reaction is stopped 
by the addition of a mixture of STOP solution and reconstituted SPA bead.  This mixture was left 
at room temperature for 30 min, followed by their count on with a Beckman LS500TD 
scintillation counter.  The mechanism behind this assays goes as follows.  If farnesyltransferase 
is present and uninhibited,  human laminin-B carboxy-terminus sequence peptide (biotin-
YRASNRSCAIM) is [3H] farnesylated at the cysteine residue. The resultant [3H]farnesyl- 
(CYS)-biotin laminin-B is captured by a streptavidin-linked SPA bead.   The scintillation fluid in 
this reaction is contained within the fluoromicrospherical SPA beads, therefore photons will only 
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be emitted if the scintillation bead comes, and remains, in close proximity to a radioactive 
compound, namely [3H]farnesyl attached to the laminin peptide. The high-affinity bond formed 
by biotn and streptavidin mediates this proximity.  If farnesyltransferase is absent or it has been 
inhibited, the [3H]farnesyl will not be attached to the laminin peptide. Therefore, no radioactive 
material will remain constantly in close proximity to the scintillation fluid to sustain the emission 
of photons. Thus, little or no counts will be observed.  This mechanism is depicted in figure 7. 
2.14 Cloning PfYKT6.2 
 
  PfYKT6.2 was amplified by RT-PCR using mRNA isolated from asynchronous parasites.  
The amplified cDNA was cloned into the T7 polymerase-driven bacterial expression vector 
pET30 vector using Ligation Independent Cloning according to manufacturers instructions 
(Novagen).  Primers were designed using Primer Select (Lasergene) [forward: 
GACGACGACAAGATGAATTTATTAGCAA and reverse: 
GAGGAGAAGCCCGGTTCACATAATGCTGC] and used to amplify the 627bp open reading 
frame. The PCR product was purified using QIAquick PCR purification kit according 
manufactures instructions (Qiagen). The DNA was resuspended in ddH20 and quantified by 
Spectrometry (Beckman Coulter DU 640).  T4 polymerase treatment and transformation of 
competent cell were performed according to manufacturer’s instructions. After plating 150µl of 
transformed cells on kanamycin plates (50µg/ml),  colonies were allowed to grow overnight. A 
few colonies were selected and grown over night for mini-prep using Qiagen’s spin mini-prep kit  
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according to protocol. Positive clones were identified by digestion with NdeI and XhoI 
restriction endonucleases (promega) in a 20 µl reaction followed by sequencing (as described 
below).  Plasmids with correct insert sequence were electroporated into BL21 DE3 
electrocompetent cells using a Bio RAD Gene Pulser II, incubated in 300µl S.O.C. medium and 
plated on kanamycin plates. Glycerol stocks were also made 
2.15 Expression of Recombinant Protein 
 
Bacterial cultures (BL21-DE3) were grown in 5ml LB broth over night at 37°C with 
shaking at 220 rpm. Overnight culture was added to 500ml LB and grown at 37°C with shaking 
until the optical density (at 600nm) of 0.6 was reached.  At this point culture was induced by the 
addition of IPTG to 0.5 µM. Induction continued for eight hours at 25°C with shaking. Culture 
was subsequently spun at 4000 × g for twenty minutes at 4°C. Pellets were then washed in 
Extraction/Wash Buffer (50mM sodium phosphate, 300mM NaCl, 10% glycerol, pH 7.0) and 
spun at 4000 × g for twenty minutes. Pellets were stored at -80°C. 
2.16 Purification of PfYKT6 
 
Purification of recombinant proteins was performed using TALON™ Super-flow Resin 
(Clontech Laboratories, Inc.). Induced frozen cell pellets were thawed and re-suspendedby 
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vortexing in Extraction/Wash Buffer (50mM sodium phosphate, 300mM NaCl, 10% glycerol, 
pH 7.0) containing one tablet of EDTA free protease inhibitor/10ml (Roche).  Cell lysis was 
achieved by passing samples through a French press (LSM-Aminco) and by sonication with a 
microtip for 4–15 seceond cycles. Cell extracts were then centrifuged at 12,000 × g for 20 
minutes at 4°C and the pellet is discarded.  The supernatant was subsequently mixed with 
TALON™ Superflow Resin, which had been previously equilibrated with Extraction/Wash 
buffer, in a 50ml centrifuge tube on a platform shaker for 20 minutes at 4°C.  The loaded resin is 
then centrifuged at 700 × g and the supernatant is removed.  The resin in washed twice with 10 
bed volumes of Extraction/Wash (either Extraction/wash or Denaturing, depending on the 
sample) containing 20M and 50mM imidazole.  After clearing the sample, the resin is transferred 
into a 2ml column (Cell Thru- Clontech Laboratories, Inc.) and washed with 5 bed volumes of 
Extraction/Wash containing 50 mM imidazole.  Purified protein was then eluted by adding 10 
bed volumes of Extraction/Wash containing 150 mM imidazole.   Ten 1 ml fractions were 
collected and run on a SDS-PAGE. Fractions with greatest amount of purified protein are 
concentrated using a Centricon filter with a 10kDa cut-off. 
2.17 DNA Sequencing 
 
Cloned fragments were sequenced using a dye terminator kit (Beckman Coulter CEQ 
DTCS Quick Start).  Fifty femto moles of template were used in each reaction.  If the DNA to be 
sequenced was located in a plasmid, then the DNA was diluted in five µl ddH2O and heated to 
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96°C for one minute.  This mixture was then allowed to cool to room temperature. One µl of a 5 
µM primer and 4 µl of DTCS was added. After the PCR reaction, (96°C twenty sec., 50°C 
twenty sec., 60°C four min.) peptide sequences were precipitated by adding 2 µl of a 50:50 mix 
of NaOAc and EDTA. One half-microliter glycogen was added to act as a carrier. Next 60 µl of 
95% EtOH at -20°C as added.  This was then spun for fifteen minutes at 14,000 × g at 4°C.  The 
precipitate was washed twice with ice cold 75% EtOH and spun for two minutes at 14,000 × g at 
4°C. The pellet was then spun to dryness in a speedvac and re-suspended in 20 µl sample loading 
solution (Beckman Coulter).  The purified sequencing product was analyzed by a Beckman 
Coulter CEQ 2000 XL running CEQ 2000 software.  Contigs were aligned and analyzed with 
Megalign and Seqman. 
2.18 In vitro Inhibition of Ftase Activity. 
 
In vitro inhibition assay was performed using 2µg partially purified Ftase, 20g 
recombinantly expressed and purified PfYKT6, 0.25µCi [3H] farnesylpyrophosphate (American 
Radiolabeled Chemicals) and buffer (50 mM Tris, 3mM MgCl, 1mM DTT, 50MZnCl2) in a 
final volume of 25 µl.  Inhibitor (FTI-276), where applicable, was added in a volume of 1µl and 
the volume of buffer was adjusted accordingly so that the final volume remained the same. 
Samples were mixed, incubated for one hour in 37°C  water bath, resolved on a 12% SDS-
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PAGE.  The gel was fixed, dried and subjected to fluorography for 21 days (details in next 
section). 
2.19 SDS PAGE, Gel Fixing and Protein Transfer  
 
Proteins samples were denatured in 4X sample buffer (250mM Tris pH 6.8, 8% 
SDS, 40% glycerol, 20% p-mercaptoethanol) and boiled for 5 minutes before separating 
on a SDS poly-acrylamide gel. Protein samples were resolved on SDS- 
polyacrylamide gels according to the method of Laemmli, 1970.  If the gel contains tritiated 
chemicals, it must be fixed with a 60:25:10 solution of Water:Ethanol:Acetic acid and with 
Amplify (Amersham Biosciences) for thirty minutes on a platform shaker. Gels are subsequently 
dried and exposed to x-ray film using an intensifying screen (Kodak BioMax MS film and 
BioMax TranScreen LE screen.) for 7 to 28 days at -80°C. Gels containing 35S need not be 
treated.  They are dried and exposed to film (Kodak) for 45 min at -80°C. 
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3. RESULTS
3.1 Stage-Dependent prenylation of P.Falciparum Proteins 
 
In an effort to determine the prenylation profile in P.falciparum parasite cultures 
wereincubated with [3H]farnesol or [3H]geranylgeraniol .  Also, to follow the dynamics of 
Plasmodium protein prenylation with  intraerythrocytic maturation radiolabeled prenols were 
added at 6, 20, 32 hr. post synchronization and  the culture was incubated for an additional 12 
hours.  Parasites were released from erythrocytes by saponin lysis, and cell-free extracts were 
prepared from parasite pellets.. Cell extracts were then resolved on SDS-PAGE and dried gels 
were subjectiedto fluorography As can be seen from Figure 8, culture incubated with 
[3H]farnesol resulted in appearance of prenylated proteins of 50 kDa or 22-28-kDa. Figure 8A 
indicates that prenylated proteins of these sizes are predominantly found during the trophozoite-
schizont transition (lane 2) with a significantly smaller amounts in the schizont-ring transition 
(lane 3) ..During ring-early trophozoite transition (lane 1) very little prenylated proteins were 
present.. Incubation with [3H]geranylgeraniol indicated proteins only at the 22-28-kDa range.  
When compared to labeling cells with [3H]farnesol, [3H]geranylgeraniol labeling resulted in an 
ubiquitous distribution of prenylated proteins in all three time points (figure 8B).  There is, still, 
a slightly greater amount of labeled proteins in the trophozoite-schizont transition.  As a control 
to this experiment, uninfected RBCs were incubated with [3H]farnesol or [3H]geranylgeraniol  
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Figure 8.  Stage Dependent prenylation of parasites.  Synchronized parasite cultures were labeled with [3H]farnesol 
(A) or [3H]geranygeranyol (B) for 16 h starting at ring (1), trophozoite (2), and schizont (3) stages   
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and treated in the same way as the infected RBC samples.   No signal was seen on 
autoradiograph, suggesting that protein prenylation in the RBC did not play a role in the results 
obtained from infected parasites (data not shown). 
3.2 Two-dimensional separation of radiolabeled P. falciparum prenylated proteins 
 
In a further attempt to enumerate the proteins prenylated during the intraerythrocytic 
stage of the malarial parasite, samples labeled with [3H]farnesol or [3H]geranylgeraniol at 6, 20, 
32 hr. post synchronization were separated by two-dimensional electrophoresis (figures 9 and 
10).   Samples treated with [3H]farnesol showed multiple species of proteins in both the 22-28-
kDa and the 50kDa range.  As before, the 50kDa range band is mainly seen in the trophozoite-
schizont transition; interestingly, this band seems to be composed of various proteins with 
different isoelectric points.  There are several proteins in the 22-28-kDa range.  Some of these 
proteins seem to be exclusively labeled in either the trophozoite-schizont transition or schizont-
ring transition.  The two-dimensional separation of [3H]geranylgeraniol-treated samples did not 
appear as resolved as the separation of samples treated with [3H]farnesol. Still, the 22-28kDa 
band seems to be composed of proteins of various sizes and charges.  Samples from the 
trophozoite-schizont transition and schizont-ring transition seem to have greater numbers of 
basic proteins when compared with sample from the ring-early trophozoite transition. 
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3.3 Mode of prenylation of P. falciparum Proteins 
 
Once the prenylation profile of P.falciparum had been established, we focused on the 
prenyl composition of its major bands.  We wanted to investigate whether the detectedbands 
arefarnesylated or geranylgeranylated.  Asynchronous culture was labeled with [3H]prenols and  
proteins were separated by SDS-PAGE. Gels segments corresponding to prenylated proteins are 
treated with methyl iodide (releases the prenyl moieties as free prenols) followed by reverse 
phase thin layer chromatography (TLC) analysis.  The results from this analysis revealed that 
prenols released from the 50-kDa band, are only farnesol (figure 11). In contrast, the prenols 
released from each of the three bands in the 22-28-kDa range is geranylgeraniol, regardless of 
whether [3H]farnesol (figure 4) or [3H]geranylgeraniol is used as the prenol precursor and of 
stage of maturation of the culture. 
3.4 Inhibition of P.falciparum growth by prenyltransferase inhibitors. 
 
47 
We decided next to determine the efficacy of peptidomimetic inhibitors FTI-277, GGTI-
298 and GGTI-286 as antimalarials.  For this, culture is grown in media supplemented with [3H] 
hypoxanthine and incubated with inhibitor under study .  Hypoxanthine is a purine precursor and 
cell cycle progression (i.e. DNA and RNA synthesis) requires its uptake. Peptidomimetic 
inhibitor concentrations were 125µM, 12.5µM. 1.25µM, 125nM, 12.5nM. Each treatment was 
done in triplicate. Incorporation of [3H]-hypoxanthine into nucleic acids following treatment  
  
 
 
  
Figure 11  Mode of prenylation of P. falciparum proteins. Proteins in asynchronous cultures of P. falciparum were 
radiolabeled with [3H]farnesol. Gel segments corresponding to the indicated labeled prenylated proteins were cut 
out. The prenyl moieties were released as free prenols and separated by reverse phase TLC. The mobilities of 
farnesol (FOH) and geranylgeraniol (GGOH) standards are shown. 
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with peptidomimetics were plotted in graphs decribed in figures 12 thru 14.   The IC50, values 
wwere quite similar for all three inhibitors tested - around 5µM.    
 3.5 Morphological changes in inhibitor treated parasites. 
 
After we had established that peptidomimetic inhibitors indeed have an effect on 
Plasmodial replication and protein prenylation, it became imperative to study their effects on cell 
cycle progression. Synchronous culture at ring stage was treated with either 5µM or 10µM FTI-
277 and stained thin smears were made 24 h thereafter (figure 15).  Parasites treated with 
inhibitor contained an enlarged vacuole.  Control parasites at 24hr. post treatment appeared much 
to be further along in the life cycle whereas inhibitor treated parasites seem incapable to mature 
past the early trophozoite stage. 
3.6 Immunofluorescence microscopy of inhibitor treated parasites.  
 
To further study the subcellular effect of prenyltransferase inhibitors in P.falciparum, we 
used a commercially available rabbit farnesyl polyclonal antibody in an indirect 
immunofluorescence experiment.   The farnesylspecific polyclonal antibody recognizes a 
farnesyl-cysteine epitope and may have the possibility cross react with the geranylgeranyl- 
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cysteine epitope.  Synchronous culture at ring stage was incubated with both FTI-277 and GGTI-
298 in either 5µM or 10µM concentrations for 24 and 36 hours.  As can be seen in figure 16 the 
blue color represents DAPI stained DNA and indicates the position of the nucleus and the green 
represents the location of prenylated proteins. The control samples show normal malarial 
development: at 24 hours the parasite has progressed into the mature trophozoite stage and at 36 
hours the parasite is in the segmenter stage, where partitioning of the nuclear material precedes 
merozoite formation and erythrocyte rupture.  Treatment of both FTI-277 and GGTI-298 yielded 
similar results for each concentration.  Treatment of inhibitors at a concentration of 5µM  seems 
to substantially decrease the amount of prenylated proteins within the parasite whereas at 10µM 
fluorescence-labeled prenylated proteins are almost completely disappears. The inhibition of cell 
cycle progression is clearly visible when one compares the slides from the control samples with 
that of slides treated with 5µM inhibitor, where no evidence of nuclear segmentation can be seen. 
The inhibitor stops the cell cycle at the trophozoite stage with an enlarged vacuole. Treatment of 
parasites with 10µM inhibitor completely disrupts parasite maturation, resulting in an 
uncharacteristically small and un-segmented nucleus. 
3.7 Inhibition of invivo Radiolabeling of P. falciparum Prenylated Proteins. 
 
Next, we tested the effect of prenyltransferase inhibitors on protein prenylation in P. falciparum.  
Synchronous culture at the ring stage was incubated with radiolabeled isoprenol groups in  
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Figure 16.   Localization of prenylated proteins. Panel I, the synchronized control culture matured from the ring 
stage (0 h) to late trophozoites (24 h) to segmenters (36 h). The panel for 24 h shows two trophozoites in an 
erythrocyte. Panel II, 5 µM FTI-277 exposed cells at 24 and 36 h treatment. Panel III, 10 µM FTI-277 exposed cells 
at 24 and 36 h treatment; panel IV, 5 µM GGTI-298 exposed cells at 24 and 36 h treatment. Panel V, 10 µM GGTI-
298 exposed cells at 24 and 36 
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presence of either FTI-277 or GGTI-298.  The concentration of inhibitor was based on the results 
from the hypoxanthine assay.   FTI-277 and GGTI-298 were used at the following final 
concentrations: 1µM, 5µM, 10µM and 25 µM.  Figure 17 shows a labeling profile that is 
congruent to one described previously, where samples treated with either [3H]farnesol or 
[3H]geranylgeraniol have multiple bands between 22-28-kDa and samples treated with 
[3H]farnesol had an additional band at 50kDa.  A significant loss of labeling was observed at 
5µM and complete loss was observed at 25µM.  Interestingly, these effects on labeling were 
observed regardless the inhibitor used with [3H]farnesol or [3H]geranylgeraniol.  Thus both FTI-
277 and GGTI-298 can inhibit overall protein prenylation in the malarial parasite equally well.   
3.8 Effect of prenyltransferase inhibitors on protein synthesis in P. falciparum 
 
Once we had established that treatment of parasitic culture with peptidomimetic 
inhibitors showed a significant effect on parasite maturation, we investigated whether the effect 
was due to specific inhibition of the protein prenyltransferase or due to non-specific inhibition 
causing a complete breakdown of protein synthesis.  For this, we allowed parasitized RBC’s to 
grow in media containing [35S] methionine and [35S] cysteine.  Inhibitors were added to a final 
concentration of 5µM and 10µM.  After 24 hr. incubation, the samples were resolved on SDS-
PAGE and the gel was subjected to autoradiography.  Interestingly, none of the peptidomimetic  
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Figure 17.  Inhibition of in vivo radiolabeling of P. falciparum prenylated proteins with peptidomimetics. 
Asynchronous cultures of P. falciparum were labeled with 10 µCi of [3H]farnesol or [3H]geranylgeraniol for 24 h in 
the presence or absence of different concentrations of the FTI-277 (A) or GGTI-298 (B). Labeled parasite proteins 
were isolated and resolved by SDS-PAGE. Radiolabeled prenylated proteins were detected by fluorography
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inhibitors used showed an effect on protein synthesis.   This can be inferred by comparing the 
lanes that contain samples incubated with inhibitor with the control lane (figure 18). 
3.9 Identification of potentially prenylated proteins in P.falciparum. 
 
Identification of proteins that may be prenylated in the malarial parasite was obtained by 
performing an in-silico search of the genome for possible prenylation targets with a c-terminus 
sequence of CAAM (where C stands for cysteine, A stands for any aliphatic amino acid and M 
stands for methionine).  We have chosen this as the search sequence because it was observed in 
our collaborator Dr. Allen’s laboratory that CAAX peptide sequences with terminal methionine 
residue serves as the best substrates for Plasmodium farnesyltransferases. The search yielded, 
among many others, a predicted polypeptide with the C-terminus sequence of CCSIM. The 
BLAST  search of this  protein showed a high homology to yeast SNARE (soluble N-
ethylmaleimide sensitive factor attachment receptor) YKT6 sequence.  In yeast, YKT6 has been 
implicated in several trafficking steps, including vesicular transport from the endoplasmic 
reticulum (ER) to the Golgi, intra-Golgi transport, and homotypic vacuole fusion (Zhang, 2001).   
YKT6 is also the only SNARE protein that is prenylated.   
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 Figure 18.  Effect of prenyltransferase inhibitors on protein synthesis in P. Falciparum.  Parasitized RBCs were 
grown in media containing [35S] methionine and [35S] cysteine.  Inhibitors were added to a final concentration of 
5mM and 10mM.  After 24 hr. incubation, samples were resolved on SDS-PAGE and the gel was subjected to 
autoradiography. 
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3.10 Cloning of PfYKT6 
 
  The open reading frame for PfYKT6 was amplified from P. falciparum cDNA using 
primers (forward: GACGACGACAAGATGAATTTATTAGCAA and reverse: 
GAGGAGAAGCCCGGTTCACATAATGCTGC) which also contained the ligation-
independent cloning sequences required for inserting into Novagen's pET30 EK/LIC vector. The 
PCR reaction yielded a fragment of correct size (figure 19).  The fragment was subsequently 
cloned into the pET30 EK/LIC vector, electroporated into XL1Blue competent cells, and plated 
onto kanamycin plates.  Clones with correct insert were determined by digestion and sequencing. 
Positive clones were electroporated into E. coli BL21 DE3 host cells and an overnight culture 
was made in preparation for test expression.  
3.11 Test expression of PfYKT6 
 
A small amount of the overnight culture was used to innoculate fresh test tubes LB 
media.  These test tubes were incubated at 37°C until they reached an optical density (OD600) of 
0.6.   At this time a small volume of the sample was set aside for later testing.  IPTG was added 
to a final concentration of 1mM and test tubes were divided into two groups.  One group was 
incubated at 37°C and the other was incubated at 26°C.  All samples, were subsequently resolved 
on a SDS-PAGE gel and subjected to immunoblotting using anti-his antibodies (figure 20).   
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3.12 Induction and Purification of PfYKT6 
 
PfYKT6 was purified using Talon cobalt His binding resin.  To obtain sufficient material 
a 500 ml culture was induced with 0.5mM IPTG for eight hours at 25°C.  Figure 21 shows a 
SDS-PAGE gel analysis of the purified and concentrated sample.  Despite the presence of a few 
contaminating proteins, we achieved a considerable enrichment of PfYKT6, which yielded 
approximately 500µg with a final concentration of 0.99µg/µl. Some precipitation was detected 
after concentration, which may have reduced the actual yield of soluble protein in the final 
sample..  All fusion proteins were detected by western blot analysis using antibodies against the 
His-tag sequence (data not shown). 
3.13 In Vitro prenylation of PfYkt6. 
 
In an effort to test whether PfYKT6 is indeed prenylated we conducted an in-vitro 
prenylation assay.  For this, purified recombinant PfYKT6, a potentially farnesylated protein 
found in the plasmodial genome, was incubated with partially purified farnesyltransferase. We 
also tested whether or not the prenylation of PfYkt6 is inhibited by inhibitors of protein 
prenylation. We used 4µg of MONO-Q purified plasmodial protein farnesyltransferase, 20 µg 
PfYKT6 and 240 nCi and [3H] FPP.  Inhibitor was used in 1nM, 5nM, and 10nM concentrations.   
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 Figure 19.  Agarose gel electrophoresis of PfYKT6 PCR product used in cloning 
 
 
 
 
Figure 20.   Western blot analysis of PfYKT6 test expression.  Solubility of PfYKT6 is achieved with expression at 
26°C.  Panel A.  Expression carried out at 37°C.  Panel B.  Expresion carried out at 26°C.  Lane 1.Uninduced crude 
lysate. Lane2.  souluble fraction of induced sample.  Lane3. Insoluble fraction of induced sample. 
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Figure 21.  SDS-PAGE analysis of PfYKT6 TALON purification.  Lane 1.  Uninduced crude lysate.  Lane 2.  
Induced crude lysate.  Lane 3.  Purified and concentrated PfYKT6.  Arrow indicates band corresponding to PfYKT6 
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The autoradiograph (Figure 22) indicates that in-vitro prenylation of PfYKT6 occurs and that the 
inhibitor FTI-276 does exert a negative effect on this prenylation. 
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Figure 22.  In Vitro inhibition of plasmodial protein farnesyltransferase.  Purified PfYKT6 was incubated with 
partially purified farnesyltransferase in the presence and absence of peptidomimetic inhibitor FTI-276.  Lane 1.  
Control sample containing 4µg of MONO-Q purified plasmodial protein farnesyltransferase, 20 µg  PfYKT6 and 
240 nCi and [3H] FPP.  Lane 2.  Sample containing additional 1nM FTI-276.  Lane 3.  Sample containing 5nM FTI-
276.  Lane 4.  Sample containing 10 nM FTI-276. 
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4. DISCUSSION 
Major pharmaceutical companies are intensively developing inhibitors of mammalian 
protein farnesyltransferase because such compounds show great promise as anti-cancer agents in 
experimental animal models.  The vast knowledge database and diversity of putative 
prenyltransferase inhibitors makes researching the effects of such inhibitors in other organisms 
(such as Plasmodium) an attractive proposition. This "piggy back" approach is very important for 
the development of drugs to treated tropical diseases in developing countries because it will 
lower the price of these drugs due to the minimal amount of venture capital invested in their 
design.  This is a crucial point since most of people affected by malaria reside in third world 
countries and thus cannot afford the price of new drugs.  
 The ultimate goal of is to find an inhibitor that would have a higher affinity for 
plasmodial farnesyltransferase instead of its human counterpart.  Previous studies performed in 
our laboratory have indicated that PfPFT inhibitors affect plasmodial life-cycle (Chakrabarti, 
1998).  Thesepeptidomimetic inhibitors, however, showed  IC50 concentrations in the micromolar 
range and therefore may not be attractive as a lead compound.is.  An in-depth understanding of 
the prenylation mechanisms in Plasmodium is crucial for the identification of an optimal 
inhibitors.  There are differences between Plasmodial and Mammalian metabolism which are of 
importance when considering inhibitor design.  P. falciparum lack a de novo pathway for 
cholesterol synthesis (Mbaya, 1990; Vial, 1984) and Plasmodial isoprenoid metabolism has a 
closer resemblance to that of plants, utilizing the methyl erythritol phosphate biosynthetic 
pathway instead of  the mevalonate pathway (Arigoni, 1997; Flesch, 1988).  Studies on 
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metabolic labeling of prenylated proteins with radiolabeled prenols in mammalian cells have 
shown that both [3H]farnesol and [3H]geranylgeraniol can be used to label proteins (Crick 1994; 
Crick 1995). Prenols are used because the diphosphate derivatives would not be able to penetrate 
the cell membrane.  The ability to utilize prenols in such labeling experiments depends on 
enzymes that convert prenols into their diphosphate derivative (Crick, 1997).  
Incubation of P. falciparum-infected erythrocytes with either [3H]farnesol or 
[3H]geranylgeraniol yielded several radiolabeled protein bands on a SDS-PAGE.  Labeling with 
[3H]farnesol showed a prenylation profile that included proteins at 50-kDa and between 22-28 
kDa range.   Prenylation was most prevalent during trophozoite to schizont and schizont to ring 
stages of differentiation, whereas few prenylated proteins are observed in the ring to trophozoite 
stage. Labeling with [3H]geranygeranyl showed a prenylation profile that was confined to the 22-
28 kDa range.  The level of geranylgeranylation does not fluctuate as much as the level of 
farnesylation throughout the lifecycle. Similar to farnesylation, geranylgeranylation was at its 
lowest level during the ring to trophozoite transition.  In 1998, Chakrabarti et. al. demonstrated 
significant PFT and PGGT-I activity in all stages of Plasmodial intraerythrocytic development, 
thus suggesting that alterations in the prenylation profile is due to a decrease in the production of 
protein substrates for prenylation.  
Studies on the mode of prenylation pursued in this thesis indicated that the 50-kDa band 
was predominantly labeled with [3H]farnesol. Proteins in the 22-28 kDa range were almost 
exclusively geranylgeranylated, regardless of whether cells were incubated with [3H]farnesol or 
[3H]geranylgeraniol. Evidently, the radiolabeled prenols are phosphorylated to their diphosphate 
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derivatives and used for prenylation.  It is also apparent that some of the [3H]farnesyl 
diphosphate is elongated to [3H]geranylgeranyl diphosphate to account for the appearance of 
[3H]geranylgeranyl labeled proteins in 22-28-kDa range isolated from cells labeled exclusively 
with [3H]farnesol.  
Treatment of plasmodial cell cultures with peptidomimetic inhibitor FTI-277 caused a 
block in maturation of the parasite during the trophozoite stage and the appearance of an 
enlarged vacuole in retarded parasites.  These morphological disturbances are quite novel and 
were not seen in earlier studies with different peptidomimetic inhibitors (Chakrabarti, 1998).   
The indirect immunofluorescence data indicates the presence of prenylated proteins in all 
stages of P. falciparum intraerythrocytic lifecycle.  These proteins are usually contained at 
distinct subcellular foci. In the segmenter stage, these foci seem to encircle chromosomal units 
that will eventually be organized into individual nuclei.  It is to be noted that at the IC50 
concentration of 5 µM FTI-277 or GGTI-298 (panels II and IV, Fig. 16), separation of 
chromosomes into individual nuclei is affected and the whole chromosomal structure appears to 
be in the form of an unsegregated mass.  The prenylation activity data, which shows insignificant 
prenylation activity in early ring stage, can be combined with the indirect immunofluorescence 
data, which indicates the presence of prenylated proteins in rings, to suggest a low turnover rate 
of pre-existing prenylated proteins and that proteins made during the early to late trophozoite 
stages may be critical for the trophozoite to schizont transition and the viability of the parasite.  
Previous studies have reported cell-cycle or differentiation dependent protein prenylation 
in synchronized HepG2 cells (Sepp-Lorenzino, 1989) and in the seminiferous epithelium of rats 
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at different stages of spermatogenesis (O'Farrell, 1975). The latter study led the authors to 
suggest that protein prenylation could constitute an obligatory step leading to the duplication of 
the cellular genome. Studies on FTI-277 account its effects on cell cycle such as G0/G1 or G2/M 
block, depending on the cell line.  Similarly, studies on GGTI-298 activity report its ability to 
halt the cell cycle at G0/G1 (Sebti, 2000; Tamanoi, 2001).  PFT inhibitor FTI-2153 has been 
shown to inhibit formation of bipolar spindle formation and chromosome alignment (Crespo, 
2001) and  SCH66336 inhibits microtubule association of farnesylated kinetochore proteins 
CENP-E (Ashar, 2000). At this point we believe that our results indicate that FTI-277 inhibit 
plasmodial lifecycle in a manner analogous to what is seeing in mammalian cells, where bipolar 
spindle formation is inhibited following PFT inhibitor treatment.  
The resolution of malarial samples in a 2-D gel yielded a novel observation for parasites: 
the appearance distinctive prenylated proteins during specific stages of P. falciparum.  Proteins 
in the 50-kDa range were predominately found in the in trophozoite stage and appeared to be of 
the same molecular weight but different charge. These mobility differences are probably caused 
by differences in phosphorylation – a scenario described in previous publications describing 
multiple prenylated proteins of the same molecular weight that appeared to be phosphorylated 
(Dugan, 1995; Sepp-Lorenzino, 1991).  Prenylated proteins of various charges and molecular 
weights were also observed in the 22-28-kDa range from parasites at both the trophozoite and 
schizont stages. Although several proteins appear to be common to the two stages, judging from 
their position of migration, there is differential labeling with some and at least one protein is 
labeled specifically at the schizont stage. 
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The specificity of PfPFT for the amino acid at the carboxyl terminus has similarities with 
mammalian PFT, where peptides ending in methionine and glutamine are substrates.  However, 
plasmodial prenyltransferase specificity differs from its mammalian analogue in that peptides 
ending in serine, threonine, and cysteine are not substrates. Plasmodial Farnesyltransferase 
specificity has a greater similarity to specificities of other parasites’ prenyltransferases such as T. 
brucei  and Leishmania amazonesis, which farnesylate peptides terminating in methionine and 
glutamine most effectively and have poor specificity for peptides terminating with other amino 
acids (Buchner, 2000; 2002).  This data, however, only indicates part of the equations.  Buckner 
et al. (28) have demonstrated that the specificity of the T. brucei enzyme changed when a CAAX 
containing peptide with different amino acid sequence was used.    
Previous studies done in our lab have show that PFT and PGGT-I inhibitors are both 
effective at inhibiting PfPFT in vitro activity (Chakrabarti, 1998).  Our study has shown that 
such inhibitors also have an adverse effect in labeling of P. falciparum proteins in culture with 
disregard to what radiolabeled prenol substrate is used. This unusual characteristic of PfPFT 
implies the potential for development of PFT inhibitors with specificity for the malarial parasite.  
In order to gain a deeper understanding of the specificity of malarial PfPFT and 
characterization of its substrates, we designed an in vitro prenylation assay with MonoQ purified 
malaria extract containing PfPFT and a recombinantly expressed malarial protein that would 
serve as a substrate.  This substrate, PfYkt6, was identified through an in silico search of the 
malarial genome.  We were able to show that the substrate is indeed prenylated in vitro by the 
purified enzyme and that the farnesyltransferawse inhibitor FTI-276 could inhibit this reaction.  
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Thus we have been able to establish a basic understanding based onwhich future research could 
be done on the specificity of malarial prenyltransferase.  Our attempts at further charcterization 
of PfYkt6 substrate met with many difficulties.  The substrate protein was highly insoluble and 
repeated attempts at purifying it under denaturing conditions resulted in precipitation of product 
during the refolding.  The yield of soluble protein was small and multiple cycles of large scale 
purification were required to obtain viable data (data not shown).  The purification of at lease 
two other possible PfPFT substrates, PfPTP and PfDnaJ, resulted in greater difficulties.  Future 
attempts will focus on purification of these substrate proteins through GST-tag instead of His-
tag.  Substrates with variant CAAX sequence were also made using site directed mutagenesis 
(data not shown).  Studies being currently conducted in our lab with these mutated substrates will 
take us one step closer to understanding malarial prenylation and its role on the malarial life 
cycle.  
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